Larimar 10-Q: $93.5M Nine-Month Loss, $128.7M Cash Into Late Q2 2027, New Fill/Finish Form 483
LRMR sits 57% above its 52-week low of $1.915 on elevated volume (1.9× avg).
Summary
Larimar's Q3 10-Q shows a $93.5 million nine-month loss and $128.7 million of cash that runs only into late Q2 2027, plus a newly disclosed FDA Form 483 at its fill/finish manufacturer as the nomlabofusp BLA sits with the agency.
Key Events · Earnings and Guidance · LRMR
-
Q3 Loss and Cash Position Detailed
Nine-month net loss was $93.5 million versus $103.2 million a year earlier; cash, equivalents and marketable securities totaled $128.7 million at September 30, 2026.
-
Runway Falls Short of One Year
Management states cash funds operations only into late Q2 2027 and is not sufficient for at least one year from issuance, so substantial doubt about going concern remains and another raise is needed.
-
New Fill/Finish Form 483 Disclosed
The FDA issued a Form 483 to the third-party drug product fill/finish manufacturer, which is implementing a remediation plan; Larimar is qualifying a back-up fill/finish manufacturer, and any delay could push approval or launch.
-
ATM Remains the Funding Lever
Larimar sold 751,682 shares under the Guggenheim ATM in Q3 2026 at a weighted-average $4.19 for about $3.1 million net, leaving $96.9 million available for sale.
Analysis · LRMR · Life Sciences
The 10-Q puts hard numbers behind the November 16 earnings release and adds a risk factor investors had not seen in the 8-K: the FDA issued a Form 483 to Larimar's third-party drug product fill/finish manufacturer, which is now remediating while the company qualifies a back-up. That matters because the rolling BLA for nomlabofusp was completed in November 2026, and any manufacturing issue can delay acceptance or approval. Cash of $128.7 million funds operations only into late Q2 2027 — short of a full year — so another raise is likely before any approval decision, and $96.9 million of ATM capacity remains as the ready lever. Spending is shifting: R&D fell on lower manufacturing spend while G&A rose on commercial build-out for a planned Q3 2027 launch.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LRMR was trading at $3.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $313.7M. The 52-week trading range was $1.92 to $6.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.